16p13.11 (n=3), 17p11.2 (n=2), 22q11.2 (n=5), 1p36 (n=4), and 5q35.3 (n=1). Analysis for pathogenic microduplications is ongoing. Discussion: We observed a greater than expected number of syndromic microdeletions amongst the schizophrenia cohort (16/348, 4.6%), particularly CNVs already hypothesized or known to be associated with neurodevelopmental disorders. Screening for these rare genetic disorders could lead to better understanding of the pathophysiology of psychiatric disorders, as well as the prevalence of these syndromic CNVs within various psychiatric population subtypes. Correctly identifying syndromic CNVs within psychiatric populations can improve patient prognosis. Further analyses will be undertaken to define specific genes contained within the implicated CNV regions to better characterize potential genetic effects on the phenotypic presentation of SCZ patients. patients. The AKT-mTOR pathway is an important signaling cascade associated with long term plasticity and thus may contribute to cognitive dysfunction. This pathway is tightly regulated by differential phosphorylation of key proteins. AKT is a serine-threonine kinase which regulates critical cellular functions like cell survival, proliferation and growth. Prior literature suggests reduced expression of AKT in SZ. mTOR is a kinase that forms 2 distinct complexes-mTORC1 and mTORC2. mTORC1 consists of mTOR, Raptor, GβL, PRAS40 and Deptor proteins. It plays an important role in actin dynamics and acts downstream of AKT. mTORC2 consists of mTOR, Rictor, GβL, Protor, mSin1 and Deptor proteins. It facilitates ribosome biogenesis and protein translation and acts upstream of AKT. Abnormalities in the mTOR complexes can contribute to dysregulated protein synthesis, which has been implicated in SZ. Alterations in the AKT-mTOR cascade, including abnormal phosphorylation of AKT and expression of mTOR complex components, have been suggested as potential mechanisms underlying SZ pathophysiology. Therefore, we hypothesized that protein levels and/or phosphorylation status of key molecules in the AKT-mTOR pathway are altered in SZ. Methods: We used post mortem dorsolateral prefrontal cortex (DLPFC) from 22 matched pairs of SZ and comparison subjects for this study. Using western blot analysis, we measured protein levels of AKT, mTOR, GβL, Raptor, phosphorylated AKT (at S473 & T308) and phosphorylated mTOR (at S2448 & S2481). Results: We found decreased levels of AKT, phosphorylated AKT (at both S473 and T308) and GβL. We also found that the ratio of phosphorylated mTOR (at S2448) to total mTOR was decreased. Discussion: AKT requires phosphorylation at both S473 and T308 for complete activation. It can further regulate the formation of mTORC1 through Rheb. AKT is phosphorylated at S473 by active mTORC2. mTOR phosphorylation at S2448 is required for its activation in both complexes. Our findings that total AKT and its phosphorylated forms are decreased in conjunction with reduced expression of GβL and the ratio of phosphorylated mTOR (at S2448) to total mTOR suggest that the AKT-mTOR signaling pathway is downregulated in SZ DLPFC. Given the importance of this pathway in synaptic plasticity via its regulation of protein translation and cytoskeletal organization, these abnormalities may represent a mechanism underlying cognitive dysfunction in SZ. Future studies will investigate the expression levels of proteins in mTOR complexes and will determine the integrity of mTORC1 and mTORC2 complex formation in SZ.
S193. EX VIVO SIGNATURE OF PSYCHOSIS AND TREATMENT RESPONSE IN PATIENT-DERIVED NEURONS

Harvard University
Background: Postmortem studies in schizophrenia show well-replicated neuronal differences in the prefrontal cortex (PFC), specifically showing lower dendritic spine density in upper-layer cortical pyramidal neurons. Animal models that recapitulate features of psychosis also show lower dendritic spine density and synapse number in the PFC, with a more pronounced effect in upper-layer cortical neurons. Furthermore, the decrease in dendritic spines and synapses in animal models have been shown to be reversible with antipsychotic treatment. Results from postmortem brains, animal models and in vitro rodent cultures provide a strong impetus to test the hypothesis that dendritic spine biology plays an important role in the biology of schizophrenia and in mediating the effects of antipsychotic medications. Methods: To extend these findings, we studied cortical neurons generated from subjects with schizophrenia. We reprogrammed induced pluripotent stem cells (iPSCs) from human subjects with schizophrenia and from matched healthy controls. We differentiated human iPSCs along the forebrain lineage to generate mature cortical neurons. We developed a robust experimental approach to delineate and quantify spines in the dendrites as well as methods to outline and measure the spines in order to classify the different spine types. We also developed methodology for functional characterization of individual neurons using calcium imaging in the cortical neuron cultures. Results: We found that cortical neurons generated from the iPSCs of schizophrenia patients had a lower density of dendritic spines when compared to cortical neurons generated from the iPSCs of healthy control subjects. We also delineated the different composition of spine types in cortical neurons from schizophrenia patients when compared to those from healthy control subjects. In cortical neurons from schizophrenia subjects, we found that clozapine exposure in vitro leads to a robust increase in dendritic spine density. Discussion: We found that cortical neurons from iPSCs of schizophrenia subjects recapitulate the dendritic spine differences reported in postmortem brains of schizophrenia subjects. Moreover, we found that human cortical neurons from schizophrenia subjects show increased dendritic spine density when exposed in vitro to clozapine. The ability to delineate cellular features related to disease biology in iPSC-derived neurons opens the door to understand the pathophysiology of schizophrenia and lay the foundations for the development of novel therapeutics. 
University of Newcastle
Background: Schizophrenia is a severe neuropsychiatric disorder, characterised by positive and negative symptoms, and cognitive deficits. High throughput technologies such as microarrays, and more recently nextgeneration sequencing have identified numerous genetic variants and transcriptional signatures associated with schizophrenia. Over the last decade, microRNAs (miRNAs) have been found differentially expressed in both peripheral and post-mortem grey matter tissue in schizophrenia, and three
